Ovarian Cancer Clinical Trial

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

Summary

The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the investigator. The hypotheses are that pembrolizumab plus paclitaxel with or without bevacizumab is superior to placebo plus paclitaxel with or without bevacizumab, with respect to PFS per RECIST 1.1 as assessed by the investigator for participants with programmed cell death ligand 1 (PD-L1) positive tumors (Combined Positive Score [CPS] ≥1) and that pembrolizumab plus paclitaxel with or without bevacizumab is superior to placebo plus paclitaxel with or without bevacizumab, with respect to PFS per RECIST 1.1 as assessed by the investigator for all participants.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Has histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Has received 1 or 2 prior lines of systemic therapy for ovarian cancer (OC), including at least 1 prior platinum-based therapy. Participants may have received a prior poly (ADP-ribose) polymerase inhibitor (PARPi), anti-PD-1/anti-PD-L1 therapy, bevacizumab, or hormonal therapy; these will not be considered a separate line of therapy. Any chemotherapy regimen change due to toxicity in the absence of disease progression will be considered part of the same line of therapy.
Has provided documented informed consent for the study.
Has radiographic evidence of disease progression within 6 months (180 days) after the last dose of platinum-based chemotherapy for OC (i.e., platinum-resistant disease).
Is a candidate for paclitaxel chemotherapy (and bevacizumab, if using).
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 3 days before randomization.
For a female participant, she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP and uses a contraceptive method that is highly effective (with a failure rate of <1% per year).
Has radiographically evaluable disease, either measurable or nonmeasurable per RECIST 1.1, as assessed by the local site investigator.
Archival tumor tissue sample or newly obtained core or incisional/excisional biopsy of a tumor lesion not previously irradiated has been provided.
Have adequate organ function.

Exclusion Criteria:

Has nonepithelial cancers, borderline tumors, mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor and undifferentiated carcinoma.
Has primary platinum-refractory disease, defined as disease that has progressed per radiographic imaging while receiving or within 28 days of the last dose of first-line platinum-based therapy.
Has prior disease progression on weekly paclitaxel alone.
Has received >2 prior lines of systemic therapy for OC.
Has received prior systemic anticancer therapy including investigational agents or maintenance therapy (including bevacizumab maintenance therapy), within 4 weeks before randomization.
Has received prior radiation therapy within 2 weeks of start of study intervention.
Has not recovered adequately from surgery and/or any complications from the surgery.
Has received colony-stimulating factors (e.g., granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor,[GM-CSF] or recombinant erythropoietin) within 4 weeks before randomization.
Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
Has received investigational agent or has used an investigational device within 4 weeks prior to study intervention.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Has severe hypersensitivity (≥Grade 3) to pembrolizumab, paclitaxel, or bevacizumab (if using) and/or any of their excipients.
Has an active autoimmune disease that has required systemic treatment in the past 2 years.
Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
Has an active infection requiring systemic therapy.
Has a known history of human immunodeficiency virus (HIV) infection.
Has a known history of Hepatitis B or known active Hepatitis C virus infection.
Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study.
Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
Participant, in the judgement of the investigator, is unlikely to comply with the study procedures, restrictions, and requirements of the study.
Has had an allogenic tissue/solid organ transplant.

For bevacizumab treatment

Has uncontrolled hypertension.
Has current, clinically relevant bowel obstruction including related to underlying epithelial OC, abdominal fistula or gastrointestinal perforation, intra-abdominal abscess, or evidence of rectosigmoid involvement by pelvic exam.
Has a history of thrombotic disorders, hemorrhage, hemoptysis, or active gastrointestinal bleeding within 6 months before randomization.

Study is for people with:

Ovarian Cancer

Phase:

Phase 3

Estimated Enrollment:

616

Study ID:

NCT05116189

Recruitment Status:

Recruiting

Sponsor:

Merck Sharp & Dohme LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 165 Locations for this study

See Locations Near You

Marin Cancer Care ( Site 0055)
Greenbrae California, 94904, United States More Info
Study Coordinator
Contact
415-925-5000
Pacific Cancer Care ( Site 0028)
Monterey California, 93940, United States More Info
Study Coordinator
Contact
831-375-4105
Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0004)
New Haven Connecticut, 06511, United States More Info
Study Coordinator
Contact
203-688-4242
University of Florida College of Medicine-UF Health Cancer Center/Clinical Trials Office ( Site 0054
Gainesville Florida, 32610, United States More Info
Study Coordinator
Contact
352-262-1072
Sarasota Memorial Hospital ( Site 0018)
Sarasota Florida, 34239, United States More Info
Study Coordinator
Contact
941-228-1752
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0005)
Marietta Georgia, 30060, United States More Info
Study Coordinator
Contact
770-281-5124
Advocate Medical Group-Oncology ( Site 0049)
Park Ridge Illinois, 60068, United States More Info
Study Coordinator
Contact
708-873-8476
Parkview Research Center at Parkview Regional Medical Center ( Site 0027)
Fort Wayne Indiana, 46845, United States More Info
Study Coordinator
Contact
260-266-7701
St. Vincent Hospital and Health Care Center, Inc ( Site 0032)
Indianapolis Indiana, 46260, United States More Info
Study Coordinator
Contact
718-876-3740
Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0040)
Edgewood Kentucky, 41017, United States More Info
Study Coordinator
Contact
859-301-2237 x2
WK Physicians Network / Hematology Oncology Associates ( Site 0034)
Shreveport Louisiana, 71103, United States More Info
Study Coordinator
Contact
318-455-1106
Mercy Medical Center - Baltimore-Medical Oncology and Hematology ( Site 0015)
Baltimore Maryland, 21202, United States More Info
Study Coordinator
Contact
410-783-5858
University of Massachusetts Chan Medical School-Division of Gynecologic Oncology ( Site 0003)
Worcester Massachusetts, 01605, United States More Info
Study Coordinator
Contact
855-862-7763
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0007)
Hackensack New Jersey, 07601, United States More Info
Study Coordinator
Contact
551-996-5855
Roswell Park Cancer Institute ( Site 0039)
Buffalo New York, 14263, United States More Info
Study Coordinator
Contact
312-714-9271
Columbia University Medical Center ( Site 0010)
New York New York, 10032, United States More Info
Study Coordinator
Contact
212-342-1496
Novant Health Presbyterian Medical Center ( Site 0029)
Charlotte North Carolina, 28204, United States More Info
Study Coordinator
Contact
704-330-9985
Duke Cancer Institute ( Site 0038)
Durham North Carolina, 27710, United States More Info
Study Coordinator
Contact
919-684-3765
Novant Health Forsyth Medical Center ( Site 0057)
Winston-Salem North Carolina, 27103, United States More Info
Study Coordinator
Contact
704-330-9985
Aultman Hospital-Oncology Clinical Trials ( Site 0009)
Canton Ohio, 44710, United States More Info
Study Coordinator
Contact
330-363-4162
MetroHealth Medical Center-Cancer Care Center ( Site 0047)
Cleveland Ohio, 44109, United States More Info
Study Coordinator
Contact
216-778-4568
Providence Portland Medical Center ( Site 0048)
Portland Oregon, 97213, United States More Info
Study Coordinator
Contact
503-215-2075
University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0024)
Pittsburgh Pennsylvania, 15219, United States More Info
Study Coordinator
Contact
412-641-1000
Sanford Cancer Center ( Site 0064)
Sioux Falls South Dakota, 57104, United States More Info
Study Coordinator
Contact
605-328-8000
The West Clinic, PLLC dba West Cancer Center ( Site 0058)
Germantown Tennessee, 38138, United States More Info
Study Coordinator
Contact
404-281-9480
Texas Oncology - The Woodlands_Lee ( Site 0043)
The Woodlands Texas, 77380, United States More Info
Study Coordinator
Contact
281-296-0365
Inova Schar Cancer Institute ( Site 0019)
Fairfax Virginia, 22031, United States More Info
Study Coordinator
Contact
571-472-1787
Westmead Hospital-Department of Gynaecological Oncology ( Site 0201)
Westmead New South Wales, 2145, Australia More Info
Study Coordinator
Contact
+61298818421
Gallipoli Medical Research Foundation-GMRF CTU ( Site 0202)
Brisbane Queensland, 4120, Australia More Info
Study Coordinator
Contact
+61733947284
Epworth Freemasons ( Site 0204)
Melbourne Victoria, 3002, Australia More Info
Study Coordinator
Contact
+61385595000
St. John of God Subiaco Hospital ( Site 0203)
Subiaco Western Australia, 6008, Australia More Info
Study Coordinator
Contact
+61893829174
Institut Jules Bordet-Medicine Oncology ( Site 0302)
Bruxelles Bruxelles-Capitale, Region De, 1000, Belgium More Info
Study Coordinator
Contact
+32 2 541 32 20
UZ Gent-Medical oncology ( Site 0301)
Gent Oost-Vlaanderen, 9000, Belgium More Info
Study Coordinator
Contact
0032 9 332 40 81
UZ Leuven ( Site 0303)
Leuven Vlaams-Brabant, 3000, Belgium More Info
Study Coordinator
Contact
+3216347419
AZ Groeninge Campus Kennedylaan-Oncology ( Site 0305)
Kortrijk West-Vlaanderen, 8500, Belgium More Info
Study Coordinator
Contact
+3256633943
Hospital Araújo Jorge ( Site 0401)
Goiânia Goias, 74605, Brazil More Info
Study Coordinator
Contact
556232437260
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0404)
Natal Rio Grande Do Norte, 59075, Brazil More Info
Study Coordinator
Contact
+558440095595
ANIMI - Unidade de Tratamento Oncologico ( Site 0408)
Lages Santa Catarina, 88501, Brazil More Info
Study Coordinator
Contact
+554933805200
BP - A Beneficencia Portuguesa de São Paulo ( Site 0403)
São Paulo Sao Paulo, 01323, Brazil More Info
Study Coordinator
Contact
+551135056541
Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0405)
São Paulo Sao Paulo, 04014, Brazil More Info
Study Coordinator
Contact
+551144500300
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA-Pesquisa Clinica HC II ( Site 0402)
Rio de Janeiro , 20220, Brazil More Info
Study Coordinator
Contact
552122764964
BC Cancer Abbotsford ( Site 0512)
Abbotsford British Columbia, V2S 0, Canada More Info
Study Coordinator
Contact
6048514744
BC Cancer Victoria ( Site 0513)
Victoria British Columbia, V8R 6, Canada More Info
Study Coordinator
Contact
2505195570
Kingston Health Sciences Centre-Kingston General Hospital Si-Oncology and/or Hematology - Gynecolog
Kingston Ontario, K7L 2, Canada More Info
Study Coordinator
Contact
613-549-6666 x 6641
Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0508)
Toronto Ontario, M4N 3, Canada More Info
Study Coordinator
Contact
416-480-5000 x7387
CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 0501)
Montreal Quebec, H1T 2, Canada More Info
Study Coordinator
Contact
514-252-3400 x5766
Jewish General Hospital ( Site 0505)
Montreal Quebec, H3T 1, Canada More Info
Study Coordinator
Contact
514-340-8222 ext. 24551
McGill University Health Centre ( Site 0502)
Montréal Quebec, H4A 3, Canada More Info
Study Coordinator
Contact
514-934-1934 x31975
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0
Quebec City Quebec, G1J 1, Canada More Info
Study Coordinator
Contact
418-691-5781
James Lind Centro de Investigación del Cáncer ( Site 0602)
Temuco Araucania, 48008, Chile More Info
Study Coordinator
Contact
+56995579412
CIDO SpA-Oncology ( Site 0608)
Temuco Araucania, 48101, Chile More Info
Study Coordinator
Contact
+569 5 798 31 73
Clínica Puerto Montt ( Site 0601)
Puerto Montt Los Lagos, 55002, Chile More Info
Study Coordinator
Contact
+56998634501
Oncovida ( Site 0603)
Santiago Region M. De Santiago, 75100, Chile More Info
Study Coordinator
Contact
+56961064692
Instituto de Radiomedicina-hemato-oncologia ( Site 0604)
Santiago Region M. De Santiago, 76303, Chile More Info
Study Coordinator
Contact
+562 275 41705
Clínica Vespucio-Hemato - Ocology ( Site 0607)
Santiago Region M. De Santiago, 82414, Chile More Info
Study Coordinator
Contact
+56 23210 0060
Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 0609)
Santiago Region M. De Santiago, 83300, Chile More Info
Study Coordinator
Contact
+56223547919
Bradfordhill ( Site 0605)
Santiago Region M. De Santiago, 84203, Chile More Info
Study Coordinator
Contact
+562 294 90970
Beijing Cancer hospital ( Site 0711)
Beijing Beijing, 10014, China More Info
Study Coordinator
Contact
13641356816
Beijing Peking Union Medical College Hospital-Gynecological center of tumor ( Site 0702)
Beijing Beijing, 10073, China More Info
Study Coordinator
Contact
13910217876
Fujian Provincial Cancer Hospital ( Site 0713)
Fuzhou Fujian, 35001, China More Info
Study Coordinator
Contact
13805015679
Lanzhou university second hospital ( Site 0734)
Lanzhou Gansu, 73003, China More Info
Study Coordinator
Contact
0931-8942856
Zhujiang Hospital ( Site 0739)
Guangzhou Guangdong, 51028, China More Info
Study Coordinator
Contact
13825013170
Guangxi Medical University Affiliated Tumor Hospital ( Site 0717)
Nanning Guangxi, 53002, China More Info
Study Coordinator
Contact
15278015900
Hainan General Hospital ( Site 0736)
Haikou Hainan, 57031, China More Info
Study Coordinator
Contact
13876082272
Henan Cancer Hospital ( Site 0718)
Zhengzhou Henan, 45000, China More Info
Study Coordinator
Contact
0371 65587588
Wuhan Union Hospital-Medical Oncology ( Site 0735)
Wuhan Hubei, 43002, China More Info
Study Coordinator
Contact
027-85726114
Hubei Cancer Hospital-Hubei Cancer Hospital ( Site 0708)
Wuhan Hubei, 43007, China More Info
Study Coordinator
Contact
+8602787671778
Xiangya Hospital Central South University-Gynecology ( Site 0705)
Changsha Hunan, 41000, China More Info
Study Coordinator
Contact
+8615116296585
Hunan Cancer Hospital ( Site 0704)
Changsha Hunan, 41001, China More Info
Study Coordinator
Contact
0731-88651669
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology (
Nanjing Jiangsu, 21000, China More Info
Study Coordinator
Contact
+8615996232819
Zhongda Hospital Southeast University ( Site 0723)
Nanjing Jiangsu, , China More Info
Study Coordinator
Contact
8615366166769
Jiangxi Maternal and Child Health Hospital-Oncology Department ( Site 0716)
Nanchang Jiangxi, 33000, China More Info
Study Coordinator
Contact
0791-86224432
The First Hospital of Jilin University ( Site 0710)
Changchun Jilin, 13002, China More Info
Study Coordinator
Contact
0431-88786014
Shandong Cancer Hospital-Oncology Department ( Site 0733)
Jinan Shandong, , China More Info
Study Coordinator
Contact
0539-8121800
LinYi Cancer Hospital ( Site 0731)
Linyi Shandong, 27600, China More Info
Study Coordinator
Contact
0539-8121800
Obstetrics & Gynecology Hospital of Fudan University ( Site 0715)
Shanghai Shanghai, 20001, China More Info
Study Coordinator
Contact
13918818816
Fudan University Shanghai Cancer Center-Gynecologic Oncology Department ( Site 0701)
Shanghai Shanghai, 20003, China More Info
Study Coordinator
Contact
021-64175590
West China Second University Hospital Sichuan University ( Site 0740)
Chengdu Sichuan, 61006, China More Info
Study Coordinator
Contact
+8618180609015
Tianjin Medical University Cancer Institute and Hospital ( Site 0720)
Tianjin Tianjin, 30006, China More Info
Study Coordinator
Contact
1862221098
Yunnan Province Cancer Hospital-Gynecology Department ( Site 0714)
Kunming Yunnan, 65010, China More Info
Study Coordinator
Contact
+8613888087358
The Affiliated Women's Hospital of Zhejiang University-Obstetrics and Gynecology ( Site 0741)
Hangzhou Zhejiang, 31000, China More Info
Study Coordinator
Contact
0571-89992206
The First Affiliated Hospital of Wenzhou Medical University-Gynecology ( Site 0706)
Wenzhou Zhejiang, 32500, China More Info
Study Coordinator
Contact
0577-55579590
Clínica Vida Fundación - Sede Poblado ( Site 0808)
Medellin Antioquia, 05003, Colombia More Info
Study Coordinator
Contact
3147362301
Clínica Universitaria Colombia ( Site 0806)
Bogotá Distrito Capital De Bogota, 11132, Colombia More Info
Study Coordinator
Contact
3152090002
Oncologos del Occidente ( Site 0807)
Pereira Risaralda, 66000, Colombia More Info
Study Coordinator
Contact
603187715522
Hemato Oncologos SA ( Site 0801)
Cali Valle Del Cauca, 76001, Colombia More Info
Study Coordinator
Contact
3229652506
Aalborg Universitetshospital, Syd ( Site 0901)
Aalborg Nordjylland, 9000, Denmark More Info
Study Coordinator
Contact
+45097660000
Turku University Hospital-Department of Obstetrics and Gynecology ( Site 1001)
Turku Varsinais-Suomi, 20520, Finland More Info
Study Coordinator
Contact
+358405465398
Centre Hospitalier Régional Universitaire de Brest - Hôpital-Institut de cancérologie et hématologi
Brest Bretagne, 29200, France More Info
Study Coordinator
Contact
+33298223985
Centre François Baclesse-Recherche clinique ( Site 2904)
Caen Calvados, 14076, France More Info
Study Coordinator
Contact
02.31.45.50.02
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren-oncologie ( Site 2907)
Limoges Haute-Vienne, 87042, France More Info
Study Coordinator
Contact
33555056396
Institut Curie - site Saint-Cloud ( Site 2909)
Saint-Cloud Hauts-de-Seine, 92210, France More Info
Study Coordinator
Contact
+33147111676
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 2901)
Rennes Ille-et-Vilaine, 35042, France More Info
Study Coordinator
Contact
+33299253280
Centre de Cancérologie du Grand Montpellier ( Site 2908)
Montpellier Languedoc-Roussillon, 34070, France More Info
Study Coordinator
Contact
0467926155
Hôpital privé du Confluent SAS-Service d'oncologie médicale ( Site 2905)
Nantes Loire-Atlantique, 44277, France More Info
Study Coordinator
Contact
+33 (0)2 28 27 21 56
Universitaetsklinikum Erlangen-Klinik für Gynäkologie und Geburtshilfe ( Site 1205)
Erlangen Bayern, 91054, Germany More Info
Study Coordinator
Contact
+4991318543463
Universitätsklinikum Bonn-Gynaecological oncology ( Site 1203)
Bonn Nordrhein-Westfalen, 53127, Germany More Info
Study Coordinator
Contact
+49 211 81-07591
Universitaetsklinikum Duesseldorf-Klinik für Frauenheilkunde & Geburtshilfe ( Site 1204)
Düsseldorf Nordrhein-Westfalen, 40225, Germany More Info
Study Coordinator
Contact
+492118117506
Zentrum fuer ambulante gynaekologische Onkologie (ZAGO) ( Site 1207)
Krefeld Nordrhein-Westfalen, 47805, Germany More Info
Study Coordinator
Contact
+492151322969
CaritasKlinikum Saarbrücken St. Theresia ( Site 1211)
Saarbrücken Saarland, 66113, Germany More Info
Study Coordinator
Contact
+496814061301
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur
Dresden Sachsen, 01307, Germany More Info
Study Coordinator
Contact
+493514586728
Charité Campus Virchow-Klinikum ( Site 1201)
Berlin , 13353, Germany More Info
Study Coordinator
Contact
+4930450564002
Asklepios Kliniken Hamburg-Asklepios Klinik Barmbek ( Site 1214)
Hamburg , 22307, Germany More Info
Study Coordinator
Contact
0401818825550
St. James's Hospital-Cancer clinical trials office ( Site 2821)
Dublin , D08 E, Ireland More Info
Study Coordinator
Contact
+353 1 410 3900
Emek Medical Center-Gyn-Onc ( Site 1406)
Afula , 18341, Israel More Info
Study Coordinator
Contact
+97254645910
Soroka Medical Center ( Site 1404)
Be'er Sheva , 84101, Israel More Info
Study Coordinator
Contact
97286400060
Rambam Health Care Campus-Gyneco-oncology unit ( Site 1402)
Haifa , 31096, Israel More Info
Study Coordinator
Contact
+972544850251
Shaare Zedek Medical Center ( Site 1405)
Jerusalem , 91031, Israel More Info
Study Coordinator
Contact
+779055424
Rabin Medical Center ( Site 1401)
Petah-Tikva , 49100, Israel More Info
Study Coordinator
Contact
972533396310
Sheba Medical Center ( Site 1407)
Ramat Gan , 52621, Israel More Info
Study Coordinator
Contact
97235303157
Sourasky Medical Center ( Site 1403)
Tel Aviv , 64239, Israel More Info
Study Coordinator
Contact
+972526861315
IRCCS - AOU di Bologna-SSD Oncologia medica Addarii ( Site 1501)
Bologna Emilia-Romagna, 40138, Italy More Info
Study Coordinator
Contact
+39 0512144548
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1503)
Milan Lombardia, 20133, Italy More Info
Study Coordinator
Contact
390223903991
Ospedale San Gerardo-ASST Monza-Oncologia ( Site 1508)
Monza Lombardia, 20900, Italy More Info
Study Coordinator
Contact
+390392334598
ASST Grande Ospedale Metropolitano Niguarda ( Site 1505)
Milan Milano, , Italy More Info
Study Coordinator
Contact
+390264442291
Ospedale Mauriziano-Ginecologia e Ostetricia ( Site 1507)
Torino Piemonte, 10128, Italy More Info
Study Coordinator
Contact
0115082764
Azienda Ospedaliera Spedali Civili di Brescia ( Site 1504)
Brescia , 25123, Italy More Info
Study Coordinator
Contact
+390303995482
Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 1502)
Milano , 20141, Italy More Info
Study Coordinator
Contact
+390257489543
Aichi Cancer Center Hospital ( Site 1610)
Nagoya Aichi, 464-8, Japan More Info
Study Coordinator
Contact
+81-52-762-6111
National Cancer Center Hospital East ( Site 1609)
Kashiwa Chiba, 277-8, Japan More Info
Study Coordinator
Contact
+81-4-7133-1111
National Hospital Organization Shikoku Cancer Center ( Site 1603)
Matsuyama Ehime, 791-0, Japan More Info
Study Coordinator
Contact
+81-89-999-1111
Ehime University Hospital ( Site 1606)
Toon Ehime, 791-0, Japan More Info
Study Coordinator
Contact
+81-89-964-5111
Kurume University Hospital ( Site 1607)
Kurume Fukuoka, 830-0, Japan More Info
Study Coordinator
Contact
+81-942-35-3311
Hokkaido University Hospital ( Site 1604)
Sapporo Hokkaido, 060-8, Japan More Info
Study Coordinator
Contact
+81-11-716-1161
Iwate Medical University Hospital ( Site 1613)
Shiwa-gun Yahaba-cho Iwate, 028-3, Japan More Info
Study Coordinator
Contact
+81-19-613-7111
Saitama Medical University International Medical Center ( Site 1601)
Hidaka-shi Saitama, 350-1, Japan More Info
Study Coordinator
Contact
+81-42-984-4111
Shizuoka Cancer Center ( Site 1611)
Nagaizumi Shizuoka, 411-8, Japan More Info
Study Coordinator
Contact
+81-55-989-5222
National Cancer Center Hospital ( Site 1612)
Chuo-ku Tokyo, 104-0, Japan More Info
Study Coordinator
Contact
+81-3-3542-2511
Japanese Foundation for Cancer Research ( Site 1605)
Koto Tokyo, 135-8, Japan More Info
Study Coordinator
Contact
+81-3-3520-0111
Osaka International Cancer Institute ( Site 1602)
Osaka , 541-8, Japan More Info
Study Coordinator
Contact
+81669451181
Seoul National University Hospital ( Site 2302)
Seoul , 03080, Korea, Republic of More Info
Study Coordinator
Contact
+82220723511
Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 2303)
Seoul , 03722, Korea, Republic of More Info
Study Coordinator
Contact
+82-2-2228-8100
Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 2304)
Seoul , 05505, Korea, Republic of More Info
Study Coordinator
Contact
+82230103640
Gangnam Severance Hospital ( Site 2301)
Seoul , 06273, Korea, Republic of More Info
Study Coordinator
Contact
82 2 2019 3430
Investigación Oncofarmacéutica-Investigación clínica ( Site 1706)
La Paz Baja California Sur, 23040, Mexico More Info
Study Coordinator
Contact
+52 61 2129 7171
COI Centro Oncologico Internacional S.A.P.I. de C.V.-Investigation Unit COI ( Site 1703)
Mexico City Distrito Federal, 04700, Mexico More Info
Study Coordinator
Contact
+525554248970 ext 4015
iCan Oncology Center Centro Medico AVE ( Site 1704)
Monterrey Nuevo Leon, 64710, Mexico More Info
Study Coordinator
Contact
+528125558165 ext 1005
Centro de Investigacion Clinica de Oaxaca ( Site 1705)
Oaxaca , 68020, Mexico More Info
Study Coordinator
Contact
+52 95 1603 5559
Leids Universitair Medisch Centrum-Medical Oncology ( Site 1801)
Leiden Zuid-Holland, 2333 , Netherlands More Info
Study Coordinator
Contact
0031 71 526 3464
Erasmus Medisch Centrum-Medical Oncology ( Site 1803)
Rotterdam Zuid-Holland, 3015 , Netherlands More Info
Study Coordinator
Contact
+31107034897
Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 1804)
Utrecht , 3584 , Netherlands More Info
Study Coordinator
Contact
+31887556265
Auckland City Hospital ( Site 1901)
Auckland , 1023, New Zealand More Info
Study Coordinator
Contact
+6493074949
Universitetssykehuset Nord-Norge HF-Kreftavdelingen ( Site 2001)
Tromsø Troms, 9038, Norway More Info
Study Coordinator
Contact
47 77 62 60 00
Szpital Kliniczny im. Księżnej Anny Mazowieckiej ( Site 2103)
Warsaw Mazowieckie, 00-31, Poland More Info
Study Coordinator
Contact
+48225966512
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Gynecological Oncology Department ( Sit
Warszawa Mazowieckie, 02-78, Poland More Info
Study Coordinator
Contact
+48501699799
Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 2106)
Bialystok Podlaskie, 15-02, Poland More Info
Study Coordinator
Contact
+48606812460
Uniwersytecki Szpital Kliniczny w Bialymstoku-Uniwersyteckie Centrum Onkologii ( Site 2104)
Bialystok Podlaskie, 15-27, Poland More Info
Study Coordinator
Contact
+48602361104
Uniwersyteckie Centrum Kliniczne-Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Gi
Gdańsk Pomorskie, 80-21, Poland More Info
Study Coordinator
Contact
0048585844041
Narodowy Instytut Onkologii - Oddzial w Gliwicach-III Klinika Radioterapii i Chemioterapii ( Site 21
Gliwice Slaskie, 44-10, Poland More Info
Study Coordinator
Contact
48 32 278 86 16
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 2107)
Kielce Swietokrzyskie, 25-73, Poland More Info
Study Coordinator
Contact
48 413674315
Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Me-Oddzial Ginekologii Onkologicznej ( Sit
Poznan Wielkopolskie, 61-84, Poland More Info
Study Coordinator
Contact
48 61 854 90 49
Chelyabinsk Regional Clinical Oncology Dispensary-Chelyabinsk Regional Clinical Oncology Dispensary
Chelyabinsk Chelyabinskaya Oblast, 45408, Russian Federation
Ogarev Mordovia State University ( Site 2209)
Saransk Mordoviya, Respublika, 43000, Russian Federation
Moscow City Oncology Hospital #62 ( Site 2214)
Krasnogorsk D-t Moskovskaya Oblast, 14342, Russian Federation
Fed State Budgetary Inst "N.N. Blokhin Med Center of Oncology" MHRF-Chemotherapy #2 ( Site 2211)
Moscow Moskva, 11547, Russian Federation
SVERDLOVSK REGIONAL ONCOLOGY DISPENSARY-Oncogynecology Department ( Site 2216)
Ekaterinburg Sverdlovskaya Oblast, 62090, Russian Federation
cukurova universty ( Site 2706)
Sarçam Adana, 01250, Turkey More Info
Study Coordinator
Contact
+905326745044
Istanbul Universitesi Cerrahpasa ( Site 2709)
Fatih Istanbul, 34098, Turkey More Info
Study Coordinator
Contact
+905334307044
Ege University Medicine of Faculty ( Site 2702)
Bornova Izmir, 35100, Turkey More Info
Study Coordinator
Contact
+905323758439
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 2704)
Adana , 01250, Turkey More Info
Study Coordinator
Contact
905327174673
Ankara University Hospital Cebeci ( Site 2701)
Ankara , 06100, Turkey More Info
Study Coordinator
Contact
00905323925195
Baskent Universitesi Ankara Hastanesi ( Site 2707)
Ankara , 34180, Turkey More Info
Study Coordinator
Contact
00905325798687
Bezmialem Vakf Üniversitesi-Oncology ( Site 2705)
Istanbul , 34093, Turkey More Info
Study Coordinator
Contact
00905324041099
T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma
Istanbul , 34440, Turkey More Info
Study Coordinator
Contact
+905323077899
Brighton and Sussex University Hospitals NHS Trust ( Site 2803)
East Sussex Brighton And Hove, BN2 5, United Kingdom More Info
Study Coordinator
Contact
01273 696955
Addenbrooke's Hospital ( Site 2808)
Cambridge Cambridgeshire, CB2 2, United Kingdom More Info
Study Coordinator
Contact
01223349701
Westmorland General Hospital ( Site 2815)
Kendal Cumbria, LA9 7, United Kingdom More Info
Study Coordinator
Contact
01539 732288
Ninewells Hospital and Medical School ( Site 2826)
Dundee Dundee City, DD1 9, United Kingdom More Info
Study Coordinator
Contact
+44 (0)1382 383581
Leicester Royal Infirmary-HOPE Clinical Trials Unit ( Site 2812)
Leicester England, , United Kingdom More Info
Study Coordinator
Contact
0116 258 7598
The Royal Cornwall Hospital ( Site 2804)
Truro England, TR1 3, United Kingdom More Info
Study Coordinator
Contact
+441872258344
Hammersmith Hospital-Medical Oncology ( Site 2818)
London London, City Of, W12 0, United Kingdom More Info
Study Coordinator
Contact
0203 313 4657
Velindre Cancer Centre ( Site 2805)
Cardiff , CF14 , United Kingdom More Info
Study Coordinator
Contact
029 2061 5888

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 3

Estimated Enrollment:

616

Study ID:

NCT05116189

Recruitment Status:

Recruiting

Sponsor:


Merck Sharp & Dohme LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.